# Phase I Study of RiMO-401 With Radiation in Advanced Tumors

> **NCT06182579** · PHASE1 · TERMINATED · sponsor: **Coordination Pharmaceuticals, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Advanced Solid Tumor
- Intratumoral Injection

## Interventions

- **DRUG:** RiMO-401

## Key facts

- **NCT ID:** NCT06182579
- **Lead sponsor:** Coordination Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-02-22
- **Primary completion:** 2025-06-16
- **Final completion:** 2025-06-16
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** slow enrollment
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06182579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06182579, "Phase I Study of RiMO-401 With Radiation in Advanced Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06182579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*